focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.21
Bid: 2.21
Ask: 2.29
Change: -0.045 (-1.96%)
Spread: 0.08 (3.62%)
Open: 2.35
High: 2.37
Low: 2.21
Prev. Close: 2.295
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: RA International loss narrows as revenue grows

Thu, 07th Sep 2023 17:07

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Pantheon Resources PLC - London-based oil and gas company focused on onshore operations in the US - Agrees a private placement of 11.9 million shares at a price of GBP0.1878 each for a total USD2.8 million to IPGL Ltd, a long-term shareholder. Pantheon will use the funds to pay the full quarterly bond repayment of the same amount. Therefore, the placement is cash-neutral and should result in materially similar dilution than would have been the case had the company settled the bond repayment in shares.

----------

Immupharma PLC - London-based drug discovery and development company - Further to announcement on August 31, raises GBP130,683 via the issue of around 6.5 million shares at 2 pence each to existing retail investors, in addition to the GBP1.4 million raised in the subscription and direct subscription. Notes Lisa Baderoon, director, subscribed for 1.0 million retail offer shares.

----------

Technology Minerals PLC - London-based battery metals mining and recycling firm - Raises GBP700,000 from a long-term shareholder through the issue of convertible loan notes. The convertible loan notes carry a coupon of 12% for a term of twelve months from issue and are convertible into shares at 1.4 pence each. "The funding will support the company as it continues to advance its exploration assets up the value curve and Recyclus progresses through the commissioning phase at its Li-ion battery recycling plant and moves closer to commercial production," says Alex Stanbury chief executive.

----------

Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Announces further progress from Hikma in the development of ready-to-use injectable medicine AT307, following a recent positive pre-investigational new drug application meeting between Hikma and the US Food & Drug Administration. In January, Arecor transferred all rights and responsibility for future development and commercialisation of AT307 to Hikma as part of an earlier co-development and license agreement. Under this pact, Arecor is eligible to receive development milestone payments in addition to future recurring revenue from royalty payments upon commercialisation. Hikma has communicated to Arecor its intention to continue the development of AT307 in the US using the FDA's 505(b)(2) regulatory pathway. This pathway provides companies with an abbreviated regulatory review process when evidence of safety and clinical efficacy generated for an originator product is deemed suitable to be relied upon in new marketing applications.

----------

Egdon Resources PLC - Reading-based oil and gas explorer and producer - Further to the announcement of August 7, says Egdon, York Energy (UK) Holdings Ltd and Cuadrilla North Cleveland Ltd have executed a fully termed agreement to enable a farm-in and equalisation of interests between the PL81 and PEDL347 licences. Licences will be assigned as follows: Egdon 52.5%, Cuadrilla 25% and York 22.5%. Egdon would be appointed as the operator of the licences. As consideration, Egdon will pay 100% of the costs associated with the planning, drilling, logging, and either short term testing and completion or plugging and abandonment of a well to optimally test the Weaverthorpe prospect.

----------

Canadian General Investments Ltd - closed-end equity fund focused on Canadian firms - Reports net asset value per share at August 31 was USD57.57, resulting in year-to-date and 12-month NAV returns, with dividends reinvested, of 20.9% and 21.6%, respectively. No comparative NAV figure was given.

----------

RA International Group PLC - specialist provider of complex and integrated remote site services - Says in the six months to June 30 revenue rose 4.1% to USD30.4 million from USD29.2 million the year prior. Pretax loss narrowed to USD2.5 million from USD3.4 million with loss per share of 1.4 pence compared to 2.0p the year before. Highlights order book of USD 71 million at June 30, although this was down from USD96 million last year.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
20 Dec 2021 11:41

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

Read more
20 Dec 2021 11:22

ImmuPharma raises £3.55m to fund research pipeline

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced subscriptions and a placing to raise £3.55m on Monday, to fund its research and development pipeline as well as general working capital.

Read more
20 Dec 2021 10:15

ImmuPharma surges after raise at "significant premium" to share price

ImmuPharma surges after raise at "significant premium" to share price

Read more
29 Nov 2021 20:45

TRADING UPDATES: ImmuPharma teams with Imperial; Webis results delayed

TRADING UPDATES: ImmuPharma teams with Imperial; Webis results delayed

Read more
29 Nov 2021 13:32

ImmuPharma signs two-year collaboration deal with Imperial College

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Monday that it has signed a two-year collaboration agreement with Imperial College London.

Read more
18 Nov 2021 20:53

TRADING UPDATES: Abingdon Health swings to loss; MetalNRG in dispute

TRADING UPDATES: Abingdon Health swings to loss; MetalNRG in dispute

Read more
18 Nov 2021 15:16

ImmuPharma reports 'significant' progress since restructure

(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported "significant" positive progress on Thursday, following major changes to its board and a restructuring of senior management in August.

Read more
1 Oct 2021 11:47

IN BRIEF: Immupharma leaves Euronext Growth Brussels market

IN BRIEF: Immupharma leaves Euronext Growth Brussels market

Read more
29 Sep 2021 20:31

IN BRIEF: ImmuPharma to make cost savings as it simplifies structure

IN BRIEF: ImmuPharma to make cost savings as it simplifies structure

Read more
29 Sep 2021 13:22

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

Read more
24 Aug 2021 15:08

DIRECTOR DEALINGS: Gamesys, Capital and ActiveOps execs sell shares

DIRECTOR DEALINGS: Gamesys, Capital and ActiveOps execs sell shares

Read more
12 Aug 2021 14:17

IN BRIEF: Immupharma gets US FDA approval for Lupuzor pre-trial study

IN BRIEF: Immupharma gets US FDA approval for Lupuzor pre-trial study

Read more
12 Aug 2021 13:02

FDA gives ImmuPharma go-ahead for pharmacokinetic study

(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Thursday that the United States Food and Drug Administration (FDA) has approved the start of the pharmacokinetic study as part of its new, "optimised" international phase 3 trial of 'Lupuzor'.

Read more
30 Jul 2021 15:34

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

Read more
16 Jul 2021 11:24

IN BRIEF: ImmuPharma appoints COO Tim Franklin to board of directors

IN BRIEF: ImmuPharma appoints COO Tim Franklin to board of directors

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.